Invention Grant
- Patent Title: Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
-
Application No.: US14874524Application Date: 2015-10-05
-
Publication No.: US09771371B2Publication Date: 2017-09-26
- Inventor: Jan Elsner , Roy L. Harris , Branden Gingsee Lee , Deborah Mortensen , Garrick K. Packard , Patrick Papa , Jason Parnes , Sophie Perrin-Ninkovic , Jennifer Riggs , John Sapienza , Graziella I. Shevlin , Lida Tehrani , Jingjing Zhao
- Applicant: SIGNAL PHARMACEUTICALS, LLC
- Applicant Address: US CA San Diego
- Assignee: Signal Pharmaceuticals, LLC
- Current Assignee: Signal Pharmaceuticals, LLC
- Current Assignee Address: US CA San Diego
- Agency: Jones Day
- Main IPC: C07D487/04
- IPC: C07D487/04 ; C07D498/14 ; C07D241/20 ; C07D471/04 ; C07D471/14 ; C07D487/10 ; C07D487/14
![Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors](/abs-image/US/2017/09/26/US09771371B2/abs.jpg.150x150.jpg)
Abstract:
Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
Public/Granted literature
Information query